Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Dana Backlund Cardin"'
Autor:
Howard S. Hochster, Andrew M. Lowy, Shay Bellasea, Mai Duong, Marc R. Radke, Dana Backlund Cardin, Ignacio Garrido-Laguna, Jennifer M. Suga, Marcus S. Noel, Jordan Berlin, Michael J. Pishvaian, Florencia Jalikis, Elizabeth M. Swisher, Philip A. Philip, Katherine A. Guthrie, E. Gabriela Chiorean
Protocol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50a4d2e0c0f632703c894986b60a2ec8
https://doi.org/10.1158/1078-0432.22483598.v1
https://doi.org/10.1158/1078-0432.22483598.v1
Autor:
Howard S. Hochster, Andrew M. Lowy, Shay Bellasea, Mai Duong, Marc R. Radke, Dana Backlund Cardin, Ignacio Garrido-Laguna, Jennifer M. Suga, Marcus S. Noel, Jordan Berlin, Michael J. Pishvaian, Florencia Jalikis, Elizabeth M. Swisher, Philip A. Philip, Katherine A. Guthrie, E. Gabriela Chiorean
Table S1: BROCA-HR gene list Table S2: Best Response, TTP, OS in Patients with HR-DDR Defects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aa7244ad887ba1c96708f23ce42ce3e
https://doi.org/10.1158/1078-0432.22483595
https://doi.org/10.1158/1078-0432.22483595
Autor:
Howard S. Hochster, Andrew M. Lowy, Shay Bellasea, Mai Duong, Marc R. Radke, Dana Backlund Cardin, Ignacio Garrido-Laguna, Jennifer M. Suga, Marcus S. Noel, Jordan Berlin, Michael J. Pishvaian, Florencia Jalikis, Elizabeth M. Swisher, Philip A. Philip, Katherine A. Guthrie, E. Gabriela Chiorean
Purpose:PARP inhibitors synergize with topoisomerase inhibitors, and veliparib plus modified (m) FOLFIRI (no 5-FU bolus) had preliminary activity in metastatic pancreatic cancers. This study evaluated the safety and efficacy of second-line treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29e14e2256fbd8da39e6b01f4ebec903
https://doi.org/10.1158/1078-0432.c.6531176.v1
https://doi.org/10.1158/1078-0432.c.6531176.v1
Autor:
Howard S. Hochster, Ignacio Garrido-Laguna, Florencia Jalikis, Philip A. Philip, Marc R. Radke, Jordan Berlin, Mai Duong, Jennifer Marie Suga, Michael J. Pishvaian, Marcus Smith Noel, Katherine A. Guthrie, Shay Bellasea, Dana Backlund Cardin, E. Gabriela Chiorean, Andrew M. Lowy, Elizabeth M. Swisher
Publikováno v:
Clinical Cancer Research. 27:6314-6322
Purpose: PARP inhibitors synergize with topoisomerase inhibitors, and veliparib plus modified (m) FOLFIRI (no 5-FU bolus) had preliminary activity in metastatic pancreatic cancers. This study evaluated the safety and efficacy of second-line treatment
Autor:
Joseph Kim, Dana Backlund Cardin, Yu Shyr, Patricia LoRusso, S. Percy Ivy, Shumei Kato, Ulka N. Vaishampayan, Peter M. Glazer, Steven R. Grossman
Publikováno v:
The Oncologist
Lessons Learned Background Cediranib, a vascular endothelial growth factor receptor inhibitor, suppresses expression of BRCA1/2 and RAD51 inducing homologous recombination DNA repair deficiency (HRD) in several cancer cell lines and xenograft models
Autor:
Tiffany L Hickman, Satya Das, Jennifer G. Whisenant, Jordan Berlin, Todd E. Peterson, Robert J. Coffey, Allison S Cohen, Gary T. Smith, Kristen K. Ciombor, Cathy Eng, Henry Charles Manning, Laura W. Goff, Joe Grudzinski, Dana Backlund Cardin
Publikováno v:
Journal of Nuclear Medicine. 63:36-43
Altered metabolism is a hallmark of cancer. In addition to glucose, glutamine is an important nutrient for cellular growth and proliferation. Non-invasive imaging via positron emission tomography (PET) may help facilitate precision treatment of cance
Autor:
Yu Shyr, Kristen K. Ciombor, Gino Pineda, Yoanna Pumpalova, Chih-Yuan Hsu, Dana Backlund Cardin, Mehmet Asim Bilen, Laura W. Goff, Jordan Berlin, Ibrahim Halil Sahin, Shih Kai Chu, Christina Wu, Emily Pei Ying Lin, Satya Das, George A. Fisher, Sigurdis Haraldsdottir
Publikováno v:
Oncologist
Introduction Immune-related adverse event (IRAE) onset may represent a clinical biomarker for anti-programmed cell death protein 1 (PD-1) antibody response based on emerging evidence from patients with various advanced malignancies. This phenomenon h
Autor:
Massimo Aglietta, Tomislav Dragovich, Sara Lonardi, Michael J. Overman, Jean-Marie Ledeine, Usman Shah, Dana Backlund Cardin, Alain Hendlisz, Eric Van Cutsem, J. Gricar, María Luisa Limón, Sandzhar Abdullaev, Bart Neyns, Gabriele Luppi, Ka Yeung Mark Wong, Pilar García-Alfonso, Heinz-Josef Lenz
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(2)
PURPOSE Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) that p
Autor:
Efrat Dotan, Wells A. Messersmith, Robert Joseph Stagg, Dana Backlund Cardin, Bert H. O'Neil, Steven J. Cohen, Ann M. Kapoun, Jordan Berlin, Safi Shahda, S. Lindsey Davis, Heinz-Josef Lenz
Publikováno v:
Investigational New Drugs
SummaryVantictumab is a fully human monoclonal antibody that inhibits Wnt pathway signaling through binding FZD1, 2, 5, 7, and 8 receptors. This phase Ib study evaluated vantictumab in combination with nab-paclitaxel and gemcitabine in patients with
Publikováno v:
J Geriatr Oncol
Older patients make up the majority of patients with pancreatic cancer, with a median age of 71 years at diagnosis. However, older patients are underrepresented in clinical trials in pancreatic cancer. This study investigates trends in age distributi